Proteomics

ISSN
P 1615-9853 E 1615-9861
출판사
John Wiley & Sons Ltd.
국가
USA
발행 상태
활성

데이터베이스 수록 정보

EMBASE 2016-2020 (5년)
JCR 2001-2019 (19년)
MEDLINE 2016-2021 (6년)
SCI 2010-2019 (10년)
SCIE 2010-2021 (12년)
Scopus 2017-2020 (4년)
SJR 2002-2019 (18년)

전체 53건 중 1번부터 10번까지의 결과를 표시합니다.

2025
Article

A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis

  • Vachhani, Pankit
  • Tan, Peter
  • Watson, Anne-Marie
  • Wu, Shang-Ju
  • Baker, Ross
  • ... Lee, Jae Hoon
  • 외 17명
  • 2025-10
  • Haematologica
  • FERRATA STORTI FOUNDATION
2024
Article

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study

  • Lee, Ji Hyun
  • Choi, Jimin
  • Min, Chang-Ki
  • Park, Sung-Soo
  • Jo, Jae-Cheol
  • ... Lee, Jae Hoon
  • 외 25명
  • 2024-11
  • Haematologica
  • FERRATA STORTI FOUNDATION
Article

Long-term efficacy and safety of tucidinostat inpatients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

  • Rai, Shinya
  • Kim, Won Seog
  • Ando, Kiyoshi
  • Choi, Ilseung
  • Izutsu, Koji
  • ... Lee, Jae Hoon
  • 외 26명
  • 2024-10
  • Haematologica
  • FERRATA STORTI FOUNDATION
2023
Article

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

  • Rai, Shinya
  • Kim, Won Seog
  • Ando, Kiyoshi
  • Choi, Ilseung
  • Izutsu, Koji
  • ... Lee, Jae Hoon
  • 외 26명
  • 2023-03
  • Haematologica
  • FERRATA STORTI FOUNDATION
2020
Article

ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCEND

  • Ghia, Paolo
  • Pluta, Andrzej
  • Wach, Malgorzata
  • Lysak, Daniel
  • Kozak, Tomas
  • ... Lee, Jae Hoon
  • 외 13명
  • 2020-10
  • Haematologica
  • FERRATA STORTI FOUNDATION
2017
Article

UPDATED RESULTS OF CARFILZOMIB ASPIRE AND ENDEAVOR STUDIES, RANDOMIZED, OPEN, MULTICENTRIC, PHASE 3 IN PATIENTS (PTS) WITH MULTIPLE MYELOMA IN RECURRENCE/RESISTANT (MMRR)

  • Oriol, A.
  • Siegel, D. S.
  • Rajnics, P.
  • Minarik, J.
  • Hungria, V
  • ... Lee, J. H.
  • 외 4명
  • 2017-10
  • Haematologica
  • FERRATA STORTI FOUNDATION
Article

EFFICACY OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT APLASTIC ANEMIA; PROSPECTIVE STUDY OF KOREAN PNH COHORT

  • Choi, C. W.
  • Jang, J. H.
  • Kim, J. S.
  • Jo, D-Y
  • Lee, J-H
  • ... Lee, J. H.
  • 외 10명
  • 2017-06
  • Haematologica
  • FERRATA STORTI FOUNDATION
Article

UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • Siegel, D.
  • Oriol, A.
  • Rajnics, P.
  • Minarik, J.
  • Hungria, V.
  • ... Lee, J. H.
  • 외 4명
  • 2017-06
  • Haematologica
  • FERRATA STORTI FOUNDATION
Article

BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

  • Kim, M. K.
  • Kim, K.
  • Yoon, D. H.
  • Suh, C.
  • Moon, J. H.
  • ... Lee, J. H.
  • 외 12명
  • 2017-06
  • Haematologica
  • FERRATA STORTI FOUNDATION
Article

CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB

  • Do, Y. R.
  • Kwak, J. -Y.
  • Kim, H.
  • Kim, J. -A.
  • Kim, H. J.
  • ... Park, J.
  • 외 18명
  • 2017-06
  • Haematologica
  • FERRATA STORTI FOUNDATION
1